Written question asked by Justin Madders (Labour) on Tuesday, 22 March 2022, in the House of Commons. It was due for an answer on Thursday, 24 March 2022. It was answered by Edward Argar (Conservative) on Wednesday, 13 April 2022 on behalf of the Department of Health and Social Care.
Liothyronine
- Question
-
To ask the Secretary of State for Health and Social Care, whether he has had discussions with relevant stakeholders on reviewing prescription guidelines following the decision by the Competition and Markets Authority to fine Advanz for the inflation of the price of Liothyronine.
- Answer
-
We have met with representatives from the Thyroid Trust and Thyroid UK to discuss prescription guidelines relating to Liothyronine.
Secondary information
- Type
- Written question
- Reference
- 144938
- Session
- 2021-22
- Subjects
- Prices Prescriptions Reviews Liothyronine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-04-13 11:37:20 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/144938
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/144938
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/144938